OncoPharm cover image

Lirafugratinib + LITESPARK011

OncoPharm

00:00

Progression-Free Survival Favors Combination Therapy

John Bazar reports significantly improved progression-free survival and higher response rates with lenvatinib plus belzutifan compared with cabozantinib.

Play episode from 09:59
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app